Pentoxifylline in Patients With Ulcerative Colitis
Clinical Study Evaluating Safety and Efficacy of Pentoxifylline in Patients With Ulcerative Colitis
Ihab Elsayed Hassan
60 participants
Jan 20, 2026
INTERVENTIONAL
Conditions
Summary
Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.
Eligibility
Inclusion Criteria4
- Age ≥ 18 years
- Both male and female will be included
- Negative pregnancy test and effective contraception.
- Mild and moderate UC patients
Exclusion Criteria9
- Breast feeding
- Significant liver and kidney function abnormalities
- Diabetic patients
- Colorectal cancer patients
- Patients with severe UC
- Patients taking rectal or systemic steroids
- Patients taking immunosuppressives or biological therapies
- Addiction to alcohol and / or drugs
- Known allergy to the studied medications
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Mesalamine is the standard first line treatment of ulcerative colitis
Pentoxifylline (PTX), a methylxanthine derivative and non-selective phosphodiesterase inhibitor, has been extensively studied for its anti-inflammatory and immunomodulatory actions. It inhibits TNF-α production at the transcriptional level and downregulates several inflammatory cytokines, including IL-1β, IL-6, and interferon-γ
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07349472